Yes / High-throughput manufacturing of transdermal microneedle arrays poses a significant challenge due to the high precision and number of features that need to be produced and the requirement of multi-step processing methods for achieving challenging micro-features. To address this challenge, we report a flexible and cost-effective process chain for transdermal microneedle array manufacture that includes mould production using laser machining and replication of thermoplastic microneedles via micro-injection moulding (micromoulding). The process chain also incorporates an in-line manufacturing data monitoring capability where the variability in the quality of microneedle arrays can be determined in a production run using captured data. Optical imaging and machine vision technologies are also implemented to create a quality inspection system that allows rapid evaluation of key quality indicators. The work presents the capability of laser machining as a cost-effective method for making microneedle moulds and micro-injection moulding of thermoplastic microneedle arrays as a highly-suitable manufacturing technique for large-scale production with low marginal cost. / This research work was undertaken in the context of MICRO-MAN project (“Process Fingerprint for Zero-defect Net-shapeMICROMANufacturing”, http://www.microman.mek.dtu.dk/).MICROMAN is a European Training Network supported byHorizon 2020, the EU Framework Programme for Research andInnovation (Project ID: 674801). This research has also receivedfunding and support from two other Horizon 2020 projects:HIMALAIA (Grant agreement No. 766871) and Laser4Fun (GA no.675063).

A terapia fotodinâmica (TFD) é uma técnica não invasiva usada no tratamento de lesões de pele, como câncer basocelular, queratose actínica, e doença de Bowen, dentre outros. Basicamente, a combinação da administração de um fotossensibilizador (FS), com a irradiação de luz adequada e o oxigênio celular, gera uma série de reações oxidativas que provocam a morte do tecido. Contudo, o principal efeito colateral desta terapia é a fotossensibilidade prolongada ocasionada pela administração de fotossensibilizadores sistêmicos. Por outro lado, a via tópica não apresenta esta limitação, pois o tratamento é realizado no local da lesão através de pró-drogas. O ácido aminolevulínico, ALA, está entre as pró-drogas mais utilizadas para indução do acúmulo do agente fotossensível na pele, a protoporfirina IX, ou PpIX. Contudo, a via tópica não permite penetração suficiente e homogênea do creme para o tratamento de lesões espessas. Visando a melhoria da TFD, foram realizados estudos in vivo e in vitro. Nos estudos in vivo, técnicas mecânicas - rolos de microagulhas, tape stripping e injeção livre de agulhas foram estudadas buscando encontrar a mais eficiente nos quesitos de: promoção da penetração da pró-droga no tecido, distribuição homogênea e de indução do acúmulo de PpIX. Para isto, foi o utilizado o modelo porcino, in vivo, conhecido como o modelo que possui a pele mais similar à pele humana. Os resultados in vivo mostram que as técnicas têm resultados similares na produção de PpIX e na distribuição de porfirina mais homogênea na superfície. Além disso, todas as técnicas estudadas in vivo têm se destacado em promover uma entrega mais homogênea de ALA também na profundidade da pele quando comparadas ao grupo controle. Nos estudos in vitro, foram examinadas possíveis diferenças na capacidade de formação da PpIX e/ou de resistência de células ao tratamento por TFD entre células expressando diferentes características de transição epitélio-mesenquimal. Os resultados in vitro indicam que as células com características epitélio-mesenquimal mais acentuadas produzem mais PpIX e são mais responsivas à TFD. Estes resultados indicam que a TFD tem maior efetividade no tratamento de células mesenquimais, e os estudos in vivo mostram que no tecido normal há maior seletividade de produção na camada da epiderme e apêndices da pele sugerindo que a terapia pode ser utilizada com maior eficiência em lesões superficiais e, até mesmo diminuir as taxas de recorrência devido a heterogeneidade de distribuição do creme na pele quando umas das técnicas mecânicas são utilizadas. / Photodynamic therapy (PDT) is a noninvasive technique used to treat skin lesions, such as basal cell cancer, actinic keratosis and Bowen\'s disease. Basically, the administration of a photosensitizer (PS), combined with the illumination of adequate light and the cellular oxygen, generate a series of oxidative reactions that cause tissue death. However, the major side effect of the treatment is prolonged photosensitivity caused by the systemic administration of photosensitizers. On the other hand, the topical therapy does not show this limitation, and it is performed at the lesion site via prodrugs. The aminolevulinic acid, ALA, is the most popular pro-drug in topical PDT. This prodrug induces PpIX production that is a photosensitive porphyrin. However, when ALA is used topically, the cream does not provide enough or homogeneous penetration for the treatment of deep lesions. Therefore, with the aim of improving PDT therapy, studies in vivo and in vitro were performed. In the in vivo analysis, mechanical techniques - microneedle roller, tape stripping, and needle-free injection- were studied looking for the most effective regarding to improve the following purposes: promoting penetration of the prodrug into the tissue, homogeneous distribution, and at inducing PpIX accumulation. The evaluations were made by fluorescence spectroscopy, biopsy of skin, and fluorescence images, using the porcine model, in vivo, known as the most similar of human skin tissue. The in vivo results showed that all techniques have similar results in the production of PpIX, and perform a more homogeneous porphyrin distribution in the skin surface. Moreover, all the techniques have excelled in promoting a homogeneous distribution of PpIX in the deep of the skin when compared to the control group. In addition to the skin penetration, studies of PpIX production were performed in vitro in cells expressing different levels of epithelial-mesenchymal transition characteristics. The studies were made in regard to a possible difference in PpIX formation capacity and / or a resistance to the PDT treatment. The in vitro results showed that cells with more epithelial-mesenchymal characteristics produce more PpIX and are more responsive to the PDT therapy. These results indicate that PDT therapy may have a better effectiveness in the treatment of mesenchymal cells and also the results in vivo showed that the ALA-induced PpIX in normal tissue seems to be selective to epidermal and skin appendages, indicating that the topical therapy may be used with a higher efficiency in superficial injuries providing lower recurrence rates when they combine with one of the techniques studied.

A terapia fotodinâmica (TFD) é uma técnica não invasiva usada no tratamento de lesões de pele, como câncer basocelular, queratose actínica, e doença de Bowen, dentre outros. Basicamente, a combinação da administração de um fotossensibilizador (FS), com a irradiação de luz adequada e o oxigênio celular, gera uma série de reações oxidativas que provocam a morte do tecido. Contudo, o principal efeito colateral desta terapia é a fotossensibilidade prolongada ocasionada pela administração de fotossensibilizadores sistêmicos. Por outro lado, a via tópica não apresenta esta limitação, pois o tratamento é realizado no local da lesão através de pró-drogas. O ácido aminolevulínico, ALA, está entre as pró-drogas mais utilizadas para indução do acúmulo do agente fotossensível na pele, a protoporfirina IX, ou PpIX. Contudo, a via tópica não permite penetração suficiente e homogênea do creme para o tratamento de lesões espessas. Visando a melhoria da TFD, foram realizados estudos in vivo e in vitro. Nos estudos in vivo, técnicas mecânicas - rolos de microagulhas, tape stripping e injeção livre de agulhas foram estudadas buscando encontrar a mais eficiente nos quesitos de: promoção da penetração da pró-droga no tecido, distribuição homogênea e de indução do acúmulo de PpIX. Para isto, foi o utilizado o modelo porcino, in vivo, conhecido como o modelo que possui a pele mais similar à pele humana. Os resultados in vivo mostram que as técnicas têm resultados similares na produção de PpIX e na distribuição de porfirina mais homogênea na superfície. Além disso, todas as técnicas estudadas in vivo têm se destacado em promover uma entrega mais homogênea de ALA também na profundidade da pele quando comparadas ao grupo controle. Nos estudos in vitro, foram examinadas possíveis diferenças na capacidade de formação da PpIX e/ou de resistência de células ao tratamento por TFD entre células expressando diferentes características de transição epitélio-mesenquimal. Os resultados in vitro indicam que as células com características epitélio-mesenquimal mais acentuadas produzem mais PpIX e são mais responsivas à TFD. Estes resultados indicam que a TFD tem maior efetividade no tratamento de células mesenquimais, e os estudos in vivo mostram que no tecido normal há maior seletividade de produção na camada da epiderme e apêndices da pele sugerindo que a terapia pode ser utilizada com maior eficiência em lesões superficiais e, até mesmo diminuir as taxas de recorrência devido a heterogeneidade de distribuição do creme na pele quando umas das técnicas mecânicas são utilizadas. / Photodynamic therapy (PDT) is a noninvasive technique used to treat skin lesions, such as basal cell cancer, actinic keratosis and Bowen\'s disease. Basically, the administration of a photosensitizer (PS), combined with the illumination of adequate light and the cellular oxygen, generate a series of oxidative reactions that cause tissue death. However, the major side effect of the treatment is prolonged photosensitivity caused by the systemic administration of photosensitizers. On the other hand, the topical therapy does not show this limitation, and it is performed at the lesion site via prodrugs. The aminolevulinic acid, ALA, is the most popular pro-drug in topical PDT. This prodrug induces PpIX production that is a photosensitive porphyrin. However, when ALA is used topically, the cream does not provide enough or homogeneous penetration for the treatment of deep lesions. Therefore, with the aim of improving PDT therapy, studies in vivo and in vitro were performed. In the in vivo analysis, mechanical techniques - microneedle roller, tape stripping, and needle-free injection- were studied looking for the most effective regarding to improve the following purposes: promoting penetration of the prodrug into the tissue, homogeneous distribution, and at inducing PpIX accumulation. The evaluations were made by fluorescence spectroscopy, biopsy of skin, and fluorescence images, using the porcine model, in vivo, known as the most similar of human skin tissue. The in vivo results showed that all techniques have similar results in the production of PpIX, and perform a more homogeneous porphyrin distribution in the skin surface. Moreover, all the techniques have excelled in promoting a homogeneous distribution of PpIX in the deep of the skin when compared to the control group. In addition to the skin penetration, studies of PpIX production were performed in vitro in cells expressing different levels of epithelial-mesenchymal transition characteristics. The studies were made in regard to a possible difference in PpIX formation capacity and / or a resistance to the PDT treatment. The in vitro results showed that cells with more epithelial-mesenchymal characteristics produce more PpIX and are more responsive to the PDT therapy. These results indicate that PDT therapy may have a better effectiveness in the treatment of mesenchymal cells and also the results in vivo showed that the ALA-induced PpIX in normal tissue seems to be selective to epidermal and skin appendages, indicating that the topical therapy may be used with a higher efficiency in superficial injuries providing lower recurrence rates when they combine with one of the techniques studied.

Wearable Microneedle (MN)-based sensors have been developed in a joint collaboration between KTH and KI in order to potentially replace invasive clinical tests such as arterial blood gas measurement. For research purposes, an IoT software platform is needed for convenient real- time observation/calibration of raw data, and observation of calibrated concentrations. In order to implement the functionality as requested by the project owners, a front-end iOS application and a back-end Node.js application were implemented. The Front-end application is written utilizing the Model-View- Viewmodel (MVVM) design pattern, allowing functionality such as creating user accounts, user login/logout, setting up a device and its micro-needles with associated analytes, observing the raw real-time analyte data in a graphical interface, calibrating the MNs aswell as observing the calibrated measurement in a graphical interface. The server-side Node.js application is designed following a Representational State Transfer (REST) architecture by utilizing the ExpressJS, MongoDB, and Mongoose object modelling libraries. The back-end application provided several Application Programming Interface (API) endpoints in order to allow fundamental Create-Read-Update-Delete (CRUD) operations for user, device, micro-needle and measurement database models. The final software products and their functionalities were tested using iOS simulators and API interaction tools by imitating real time measurements. Also, performance benchmarks were performed for two scenarios, project optimums and project extremes, both in the back-end and in the frontend software. This was in order to determine if the platform meets the project prerequisites that were set by project owners. As a result, system performance and functionality were found satisfactory for utilization in the research environment for the development of the MN-based patches. / Kroppsburna mikronåls-baserade sensorer har utvecklats i ett gemensamt samarbete mellan KTH och KI för att potentiellt kunna ersätta invasiva kliniska provtagningar som arteriell blodgasmätning. För forskningsändamål behövs en IoT-programvaruplattform för praktisk realtidsobservation samt kalibrering av sensorernas utdata. För att implementera funktionaliteten som begärdes av projektägarna, skapades en frontend-applikation för iOS-enheter vars backend bygger på en Node.js-applikation. Frontend-applikationen är skriven med hjälp av designmönstret gls MVVM, vilket möjliggör funktionalitet som skapande av användarkonton, användarinloggning samt utloggning, konfigurering av enheter och dess mikronålar med tillhörande analyserade värden, observation av realtidsdata i ett grafiskt gränssnitt, kalibrering av glspl MN samt observation av den kalibrerade mätningen i ett grafiskt gränssnitt. Node.js- applikationen på serversidan är utformad enligt gls REST -arkitekturen genom att använda objektbiblioteken ExpressJS, MongoDB samt Mongoose. Backend-applikationen tillhandahöll flera gls API-slutpunkter för att möjliggöra grundläggande gls CRUD-operationer för databaser av användare, enheter eller mikronålar. Den slutliga produkten och dess funktioner testades med hjälp av iOS- simulatorer och API-interaktionsverktyg genom att imitera realtidsmätningar från en mikronålsenhet. Dessutom utfördes prestandatest för två scenarier, optimala samt extrema förhållanden, både i backend samt frontend- programvaran. Detta för att avgöra ifall plattformen uppfyller de krav som hade ställts av projektägarna. Systemprestanda samt funktionalitet har av testerna bedömts vara tillfredsställande för användning i forskningsmiljön för vidare utveckling av gls MN -baserade sensorer.

The major hurdle in the development of transdermal route as a versatile drug delivery method is the formidable transport barrier provided by the stratum corneum. Despite decades of research to overcome the stratum corneum barrier, limited success has been achieved. The objectives of this research were to develop and characterize two different strategies to overcome the stratum corneum barrier for transdermal delivery of biopharmaceuticals and vaccines. In the first strategy, coated microneedles (sharp-tipped, micron-sized structures) were developed to enable delivery of drugs directly into the skin by bypassing the stratum corneum barrier. In the second strategy, instead of bypassing the barrier, microdermabrasion was used to selectively abrade stratum corneum with sharp microparticles for topical drug application. Coated microneedles For developing painless microneedles, the first detailed study was performed to characterize the effect of microneedle geometry on pain caused by microneedle insertions in human volunteers. This study demonstrated that microneedles are significantly less painful than a 26-gage hypodermic needle and that decreasing microneedle length and numbers reduces pain. Next, the first in-depth study of microneedle coating methods and formulations was performed to (i) develop a novel micron-scale dip-coating process, (ii) test the breadth of compounds that can be coated onto microneedles, and (iii) develop a rational basis to design novel coating formulations based on the physics of dip-coating. Finally, a plasmid DNA-vaccine was coated onto microneedles to immunize mice, to provide the first evidence that microneedle-based skin immunization can generate a robust in vivo antigen-specific cytotoxic-T-lymphocyte response using similar, or lower, DNA doses on microneedles as when using the gene gun or intramuscular injection. Microdermabrasion We demonstrated for the first time that microdermabrasion in monkeys and humans can selectively, yet completely remove the stratum corneum layer. Using a mobile mode of microdermabrasion, an increase in the number of treatment passes led to greater tissue removal. Furthermore, topical application of Modified Vaccinia Ankara virus after microdermabrasion induced virus-specific antibodies in monkeys. In conclusion, both coated microneedles and microdermabrasion were developed to enable delivery of biomolecules into the skin, indicating their potential for transdermal delivery of a wide range of biopharmaceuticals and vaccines.

Le développement de nouveaux systèmes pour l’administration de médicaments par la voie transcutanée ne cesse de susciter un intérêt croissant pour élaborer de nouvelles stratégies visant à traverser la barrière du stratum corneum et transporter efficacement les agents thérapeutiques à travers la peau. Bien que l’administration par voie orale soit la plus favorable chez les patients, une faible biodisponibilité est souvent rencontrée pour certains médicaments et notamment pour les produits biopharmaceutiques. Ainsi, la peau représente un site accessible et pratique pour l’absorption de médicaments, mais détient un potentiel encore sous-estimé comme voie alternative à l’administration par voie orale. La conception de systèmes d'administration parentérale prolongée de médicaments capables de contrôler la libération du médicament au long terme et réduire la fréquence d’administration des médicaments pourrait présenter une option de traitement attrayante. Parmi les systèmes d’implants se formant in situ, les implants d’organogel offrent de nombreux avantages pour libérer au long terme une grande variété de molécules médicamenteuses et notamment des substances actives lipophiles piégées dans les huiles gélifiées. Cependant si l’objectif visé est une administration minimalement invasive et rapide de substances actives, les timbres de microaiguilles dissolvant dans la peau seraient d’un grand intérêt en raison de leur auto-administration, leur sécurité d’emploi et leur capacité à administrer des médicaments à base de peptides. Malgré les effets bénéfiques de ces deux nouveaux systèmes d’administration, les rôles exacts de la composition des organogels et des paramètres géométriques des microaiguilles hydrosolubles sur la libération de médicaments restent peu explorés. Le premier objectif principal de cette thèse était de déterminer l’effet de la composition des organogels se formant in situ par rapport au pourcentage massique en organogélifiant de bas poids moléculaire (acide 12-hydroxystéarique, 12-HSA) et de l’ajout de tensioactif (polysorbate 80) dans le système sur le taux de libération de substances actives hydrophile (acyclovir) et lipophile (clotrimazole). De plus, l'influence des paramètres de composition de ces organogels sur l'induction d'effets toxiques au niveau des fibroblastes de prépuce humain a également été étudiée. Pour ce faire, des systèmes d’organogel formant un dépôt sous-cutané à base de 12-HSA ont été développés en utilisant une faible quantité de solvant organique miscible à l’eau (N-méthyl-2-pyrrolidone) en tant qu’agent inhibant partiellement la gélation, favorisant ainsi l’injection des formulations. Au contact du milieu aqueux, les molécules de 12-HSA ont précipité en immobilisant simultanément l’huile et la substance active en son sein. Une augmentation du pourcentage massique en 12-HSA a conduit à une augmentation de la résistance du gel à la déformation grâce à la formation d’une structure de réseau en trois dimensions complexe. Cependant, l’ajout de polysorbate 80 dans le système a conduit à une structure plus fluide (de faible résistance) diminuant la capacité d’injectabilité des formulations et augmentant l’érosion du gel en surface. Ce dernier phénomène étant amplifié avec un plus faible pourcentage massique en 12-HSA. Les organogels de 12-HSA ont montré diminuer significativement les taux de libération au long terme de l’acyclovir comparé aux formulations de clotrimazole in vitro et ex vivo à travers la peau de porc excisé. La toxicité cellulaire était dépendante du pourcentage massique en 12-HSA et du type de culture cellulaire utilisée. En effet, les effets cytotoxiques étaient plus élevés en augmentant la quantité de 12-HSA dans l’implant pour une sensibilité plus élevée dans la culture cellulaire tridimensionnelle que dans celle bidimensionnelle. Ces résultats semblent néanmoins influencés par le type d’huile utilisé et son potentiel cytotoxique. Le deuxième objectif principal de cette thèse était de déterminer l’effet de la hauteur des microaiguilles en forme de pyramide et solubles dans l’eau sur le taux de libération d’un peptide modèle, le growth hormone-releasing peptide-6 (GHRP-6). À cet effet, les microaiguilles ont été préparées par micro-moulage à l’aide de deux polymères biocompatibles hydrosolubles approuvés par la Food and Drug Agency (FDA), l’alcool polyvinylique (PVA) et polyvinylpyrrolidone (PVP). Les timbres de microaiguilles ainsi développés permettaient de pénétrer efficacement dans la peau de porc tout en libérant la molécule encapsulée à l’interface entre l’épiderme et le derme supérieur. La quantification du GHRP-6 dans différentes matrices (peau, microaiguilles, plasma) a pu être réalisée grâce à une méthode analytique robuste et sensible utilisant la chromatographie liquide ultra performance couplée à la spectrométrie de masse en tandem. Les études de libération du GHRP-6 ex vivo sur la peau de porc ont montré que le taux de libération du GHRP-6 était plus élevé au long terme pour une hauteur en aiguille plus grande (800 µm contre 500 µm) tout en permettant d’augmenter l’encapsulation du GHRP-6 dans le système. En conclusion, ces résultats suggèrent que les organogels de 12-HSA pourraient constituer une approche prometteuse pour l’administration prolongée de substance active et notamment celles hydrophiles. Toutefois, les formulations développées devront être efficaces in vivo tout en minimisant les effets toxiques par l’utilisation d’huiles plus biocompatibles. Pour une libération rapide de substances actives, les timbres de microaiguilles représentent une avenue très prometteuse notamment pour les médicaments innovants de nature peptidique. Leur efficacité pour la libération de GHRP-6 et de leurs dérivés azapeptides devra être confirmée lors d’études in vivo (pharmacocinétique, pharmacodynamique, biodistribution), ce qui pourrait constituer une avancée dans l’administration de thérapie à base de peptides pour la gestion de l’inflammation chronique. / The development of novel transcutaneous drug delivery systems has gained increasing interest, with the focus on overcoming the stratum corneum barrier and efficiently transport therapeutic agents through the skin. Although oral administration is the most favorable route for patients, low bioavailability is often reported for certain drugs and especially for biopharmaceuticals. Accordingly, the skin represents an accessible and convenient site for drug absorption, but has yet to fully achieve its potential as an alternative to oral delivery. The design of parenteral sustained drug delivery systems capable of controlling long-term delivery of drugs and reducing the frequency of drug administration could present an attractive treatment option. Among in situ forming implants, in situ forming organogels offer many advantages such as controlled-release of a wide variety of drug molecules over a longer period of time, including lipophilic active substances trapped within gelled oil solutions. However, if the objective is the rapid administration of active substances, minimally invasive, dissolving microneedle patches would be of great interest due to their self-administration, their safety and their ability to deliver peptide-based drugs. Despite the beneficial effects of these two new delivery systems, the exact roles of the composition of organogels and geometrical parameters of microneedles on drug delivery are largely understudied. The first main objective of this thesis was to determine the effect of the composition of in situ forming organogels with respect to the organogelator concentration (12-hydroxystearic acid, 12-HSA) and the addition of a nonionic surfactant (polysorbate 80) to the system on the release rate of a hydrophilic (acyclovir) and a lipophilic (clotrimazole) active substances. In addition, the toxic effects of these organogels of different compositions on human foreskin fibroblasts were also studied. To do so, 12-HSA-based organogel systems forming a depot in the subcutaneous tissue have been developed using a small amount of water-miscible organic solvent (N-methyl-2-pyrrolidone) as an agent that can partially inhibit gelation, thus enhancing injectability of the formulations. Upon contact with aqueous medium, 12-HSA molecules precipitated simultaneously immobilizing the oil and the active substance therein. An increase in the concentration of 12-HSA led to an increase in the resistance of the gel to deformation thanks to the formation of a complex three-dimensional network structure. However, the addition of polysorbate 80 to the system resulted in fluid-matrix organogel (weak gel) decreasing the syringability of the formulations while increasing the erosion of the gel on the surface. The latter phenomenon is also intensified with a lower concentration of 12-HSA. 12-HSA organogels have been shown to significantly decrease acyclovir release rates for a longer time period in vitro and ex vivo through excised pig skin compared to clotrimazole formulations. Cellular cytotoxicity was dependent on the concentration of 12-HSA and the type of cell culture used. Indeed, the cytotoxic effects were higher by increasing the concentration of 12-HSA in the implant for a higher sensitivity in the three-dimensional cell culture than in the two-dimensional one. However, these results seem to be influenced by the type of oil used and its cytotoxic potential. The second main objective of this thesis was to determine the effect of dissolving pyramidal microneedles height on the release rate of a model peptide, the growth hormone-releasing peptide-6 (GHRP-6). For this purpose, the microneedles were prepared by micromolding process using two water-soluble biocompatible polymers approved by the Food and Drug Agency (FDA), poly(vinyl alcohol) (PVA) and polyvinylpyrrolidone (PVP). The microneedle patches allowed the microneedles to efficiently penetrate pig skin while releasing the encapsulated molecule at the interface between the epidermis and upper dermis. The quantification of GHRP-6 in different matrices (skin, microneedles, plasma) was achieved using a robust and sensitive analytical method using ultra performance liquid chromatography - tandem mass spectrometry. Ex vivo GHRP-6 release studies on pig skin showed that the release rate of GHRP-6 was higher over time for high-height microneedle (800 µm vs. 500 µm) while increasing the amount of GHRP-6 loaded in microneedles. In conclusion, these results suggest that 12-HSA organogels could constitute a promising approach as a sustained-release dosage form of active substances and in particular hydrophilic ones. However, the formulations developed must be effective in vivo while minimizing toxic effects through the use of more biocompatible oils. For a rapid release of drugs, microneedle patches represent a very promising avenue, in particular for emerging peptide drugs. Their efficacy for the release of GHRP-6 and azapeptide derivatives of GHRP-6 needs to be confirmed using in vivo studies (pharmacokinetic, pharmacodynamic, biodistribution), which may represent a breakthrough in the transdermal delivery of therapeutic peptides for the management of chronic inflammation.

Le liquide interstitiel est aujourd’hui considéré comme un candidat prometteur comme alternative, ou complément, à l’analyse sanguine pour la quantification de biomarqueurs. Localisé notamment dans la peau, sa composition demeure peu décrite dans la littérature. Cela peut s’expliquer par le fait que le prélèvement de liquide interstitiel reste problématique. En effet, les méthodes d’extraction actuelles sont chronophages, douloureuses et conduisent au prélèvement de volumes très faibles ne permettant pas toujours une analyse subséquente. L’utilisation de timbres de microaiguilles conçus en hydrogel superabsorbant représente une solution indolore, rapide et efficace pour le prélèvement du liquide interstitiel. Un premier type de timbre a été conçu par photopolymérisation, un processus de fabrication caractérisé par sa rapidité. Ce type de timbre de microaiguilles présente une capacité d’absorption très élevée et peut trouver une application dans l’élaboration des profils protéomique, métabolomique et lipidomique du liquide interstitiel dermique. Le second type de timbres de microaiguilles est obtenu par chauffage d’une formulation contenant des polymères superabsorbants. Ce procédé s’avère plus long mais conduit à un hydrogel superabsorbant riche en groupements chimiques permettant d’envisager une fonctionnalisation pour la capture et la détection in situ de biomarqueurs spécifiques du liquide interstitiel dermique. In fine, les timbres de microaiguilles développés pourraient donc permettre d’approfondir notre connaissance de la composition du liquide interstitiel; mais laissent également entrevoir la possibilité de développer des dispositifs médicaux portables permettant le diagnostic, ou la surveillance, rapide et indolore de certaines pathologies. Ces dispositifs pourraient diminuer les coûts normalement associés à ces pratiques et améliorer la prise en charge des patients. C’est le cas notamment de l’insuffisance cardiaque, dont la gestion pourrait être considérablement facilitée par le suivi à domicile du biomarqueur NT-proBNP. / Nowadays, interstitial fluid is considered a valid alternative for blood analysis and biomarker monitoring. However, its composition is scarcely described in the literature. Notably located in the skin, its collection remains a challenge as current methods are time-consuming, painful and the extracted volume limits subsequent analysis. Here we put forward the use of superabsorbant hydrogel-based microneedle patches to enable a painless, rapid and efficient sampling of dermal interstitial fluid. A first kind of microneedle patch was obtained using UV-curing, a rapid fabrication process. This type of microneedle patch enables the collection of a high volume of liquid and can therefore be utilized for subsequent proteomic, metabolomic and lipidomic analyses of the dermal interstitial fluid that had been extracted in a painless fashion. The second class of microneedle patch developed was fabricated from superabsorbant polymers using heating. Although time consuming, this process produced hydrogel-based microneedle patches that could be functionalized for the in situ detection of specific biomarkers in the dermal interstitial fluid. In fine, the aforementioned microneedle patches have the potential to broaden our understanding of the interstitial fluid composition, as well as be integrated in novel portable biosensing devices for a rapid and painless diagnosis, or for the monitoring of certain medical conditions. For example, quantifying the NT-proBNP biomarker in the dermal interstitial fluid could significantly improve the quality of life of heart failure patients.

<p dir="ltr">Ultra-scaled, always-on, smart, wearable and implantable (WI) therapeutic platforms define the research frontier of modern personalized medicine. The WI platform integrates real-time sensing with on-demand therapy and is ideally suited for real-time management of chronic diseases like diabetes. Traditional blood tracking methods, such as glucometers, are insufficient due to their once-in-a-while measurements and the imprecision of insulin injections, which can lead to severe complications. To address these challenges, researchers have been developing smart and minimally invasive microneedle (MN) components for pain-free glucose detection and drug delivery, potentially functioning as an "artificial pancreas". Inspired by natural body homeostasis, these platforms must be accurate and responsive for immediate corrective interventions. However, artificial MN patches often have slow readings due to factors like MN morphology and composition that remain poorly understood, hindering their optimization and integration into real-time monitoring devices. Despite extensive, iterative experimental efforts worldwide, a holistic framework incorporating the interaction between MN sensing and therapy with fluctuating natural body functions is missing. In this thesis, we propose a generalized framework for glycemic management based on the interaction between biological processes and MN-based operations. The results, incorporating theoretical insights from the 1960s and recent advancements in MN technology, are platform-agnostic. This generality offers a unique template to interpret experimental observations, justify the recent introduction of drugs like GLP-1 cocktails, and optimize platforms for accurate and fast disease management. </p>